VanEck Vectors Pharmaceutical ETF Stock Forecast, Price & News

Wall Street analysts have given VanEck Vectors Pharmaceutical ETF a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but VanEck Vectors Pharmaceutical ETF wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

VanEck Vectors Pharmaceutical ETF saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 845,800 shares, an increase of 102.7% from the February 28th total of 417,200 shares. Based on an average trading volume of 94,000 shares, the short-interest ratio is currently 9.0 days.
View VanEck Vectors Pharmaceutical ETF's Short Interest.

VanEck Vectors Pharmaceutical ETF's stock was trading at $56.63 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PPH shares have increased by 20.7% and is now trading at $68.37.
View which stocks have been most impacted by COVID-19.

VanEck Vectors Pharmaceutical ETF announced a quarterly dividend on Wednesday, March 31st. Shareholders of record on Monday, April 5th will be paid a dividend of $0.35 per share on Thursday, April 8th. This represents a $1.40 annualized dividend and a dividend yield of 2.05%. The ex-dividend date of this dividend is Thursday, April 1st. This is a positive change from VanEck Vectors Pharmaceutical ETF's previous quarterly dividend of $0.27.
View VanEck Vectors Pharmaceutical ETF's dividend history.

VanEck Vectors Pharmaceutical ETF pays an annual dividend of $1.12 per share and currently has a dividend yield of 1.65%.
View VanEck Vectors Pharmaceutical ETF's dividend history.

38 employees have rated VanEck Vectors Pharmaceutical ETF CEO Bruce Gordon on Glassdoor.com. Bruce Gordon has an approval rating of 98% among VanEck Vectors Pharmaceutical ETF's employees. This puts Bruce Gordon in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other VanEck Vectors Pharmaceutical ETF investors own include Bank of America (BAC), Alibaba Group (BABA), AeroVironment (AVAV), Activision Blizzard (ATVI), ARK Autonomous Technology & Robotics ETF (ARKQ), ARK Innovation ETF (ARKK), Applied Materials (AMAT), Applied Graphene Materials (AGM), Air Canada (AC) and Abbott Laboratories (ABT).

VanEck Vectors Pharmaceutical ETF trades on the NASDAQ under the ticker symbol "PPH."

Shares of PPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PPH stock can currently be purchased for approximately $68.37.

VanEck Vectors Pharmaceutical ETF has a market capitalization of $217.96 million.